High Affinity CYP3A4 Inhibitors
These CYP3A4 inhibitors can be co-administered with other pharmaceuticals to enhance therapeutic efficacy and decrease side effects. Pharmacophore modeling was utilized to design these compounds, resulting in highly specific binding and minimizing off-target effects. The new inhibitors presented herein are smaller and less complex than current on-the-market treatments, ritonavir and its variants. These new inhibitors have IC50 values as low or lower than ritonavir.
Cytochrome P450 enzymes, including CYP3A4, play a vital role in the metabolism of pharmaceutical drugs. In some instances, these enzymes breakdown drugs too quickly, making treatments less effective. Thusly, some drug cocktails include CYP inhibitors, which affords longer lifetimes in the body of the other active components. Currently used CYP3A4 inhibitors, such as Ritonavir (trade name Norvir), are highly active, but have undesirable, off-target effects. Using models of the CYP3A4 enzyme, the minimum and critical criteria for ligand binding have been determined. This method yielded novel inhibitors that may have better efficacy and/or less off target effects than current treatments. Like most CYP inhibitors, these molecules are short amino acid-like sequences. Preliminary assessment of two of the most promising designed inhibitors have inhibitory concentrations less than ritonavir (IC50 = 0.52 and 0.13, respectively; compared to IC50 = 0.55 for ritonavir).
State Of Development Protein binding and inhibition studies have been completed. Future studies include animal studies and utilizing these compounds for the synthesis of second generation inhibitors. Additional Technologies by these Inventors Tech ID/UC Case 25550/2015-413-0 Related Cases 2015-413-0 UC QuickStart
QuickStart Licensing
USA
